[Laboratory and clinical studies of XXXX (author's transl)].

@entity1 @entity3617 @entity1712 @entity794 @entity5389 @entity3274 @entity17444 @entity3298 @entity526
The authors have carried out the laboratory and clinical studies of @entity17444 (CXD), and obtained the following results. The antibacterial activities of CXD were measured by plate dilution method on 26 clinical isolates of @entity794 , @entity526 and @entity3274 . CXD inhibited the growth of all strains of @entity794 at concentrations less than 6.25 microgram/ml, the peak of activity distribution was obtained at 3.13 microgram/ml with an inoculum size of 10(6) cells/ml. And the p eak sensitivity distribution of @entity526 was obtained at 6.25 microgram/ml. The growth of all strains of @entity3274 was inhibited at concentrations of less than 25 microgram/ml. Phagocytosis was determined by QUIE'S method. In the presence of CXD, phagocytosis of @entity1 PMNs was not enhanced to @entity526 and @entity3274 . For pharmacokinetic study, CXD was given orally at a single dose of 10 mg/kg to 3 @entity1 before and after meals. The serum levels of CXD on fasting were 14.2 microgram/ml, 11.0 microgram/ml, 4.0 microgram/ml and 0.57 microgram/ml at 0.5, 1, 2. 4 hours after administration respectively, and the level at 6 hours was not detectable. Half-life was 0.65 hours. The serum levels of CXD after meals were 3.9 microgram/ml, 5.3 microgram/ml, 5.3 microgram/ml, 2.4 microgram/ml and 0.42 microgram/ml at 0.5, 1, 2, 4, 6 hours after administration respectively, but at 8 hours it was not detectable. Half-life was 0.95 hours. The 8-hour urinary excretion rates on fasting and non fasting were 89.4%, 89.0% respectively. CXD was given to 31 cases with @entity5389 , 4 with @entity3617 , 1 with impetigo, 3 with cervical @entity3298 , 7 with U.T.I, totalling 46. A daily dose of CXD 400 approximately 1,500 mg was given for 4 approximately 14 days. Clinical results obtained were good and excellent responses in 43/46 (93.5%) cases. No side effects were observed except for 1 case with elevation of GOT, 2 cases with elevation of GOT and GPT and 1 case with @entity1712 .
